Clinical trials: Drug Induced Liver Injury, open to volunteers
Liver Diseases
DILIN - Prospective Study
The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine.
- Trial name
- NCT00345930
- Where
- 6 sites in United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Drug Induced Liver Injury, Chronic Liver Disease
Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease
DILI is an underdiagnosed and under appreciated causal or contributing factor to liver injury. DILI can mimics features of the entire spectrum of acute and chronic liver disease.
- Trial name
- NCT06797011
- Testing
- High volume Plasma Exchange, Standard Medical Treatment
- Where
- India
- Volunteers
- 96 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV)
Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)
Evaluate the feasibility, acceptability, and usability of the intervention (primary outcomes) and coping skills and resilience (secondary outcomes) of the telehealth intervention over two months (8 weekly sessions) in a…
- Conditions
- HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), Opioid Use Disorder
- Trial name
- NCT06799702
- Testing
- Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Drug Induced Liver Injury
Drug-Induced Liver Injury (DILI) Network Retrospective
The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these…
- Trial name
- ILIAD (NCT00360646)
- Where
- 6 sites in United States
- Volunteers
- 400 people
- Sponsor
- Duke University
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Drug Induced Liver Injury, Pruritus
Drug-induced Liver Injury: Itching Study
Idiosyncratic drug-induced liver injury (DILI) is an unpredictable adverse hepatic reaction to a medication used in its therapeutic dose.
- Trial name
- NCT06446609
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Nottingham
Drug Induced Liver Injury, Tuberculosis (TB)
Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi
OBJECTIVE : To compare the outcome of treatment with silymarin or N-acetyl cysteine in patients taking anti-tuberculous drugs for tuberculosis at Tertiary Care Hospital, Karachi.
- Trial name
- NCT07058090
- Testing
- Silymarin 420 mg, N Acetyl Cysteine, Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
- Volunteers
- 410 people
- Sponsor
- Liaquat National Hospital & Medical College
Drug-induced Liver Injury
A Prognostic Model for Drug-induced Liver Injury in China
A prospective, multi-center, non-interventional cohort study is going to conduct to explore the clinical characteristics, culprit drug(s) or herb(s), outcomes and risk factors of Drug-induced liver injury (DILI) in China and…
- Trial name
- DILI-PM (NCT05060289)
- Where
- 13 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Friendship Hospital
Drug Induced Liver Injury
Prospective Comparative Validation Study of RUCAM and RECAM
A total of 407 hospitalized patients with acute liver injury in Beijing Friendship Hospital Affiliated to Capital Medical University were enrolled.
- Trial name
- NCT06771011
- Where
- China
- Volunteers
- 407 people
- Sponsor
- Beijing Friendship Hospital
Liver Injury, Secondary to Immune Checkpoint Inhibitors
Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Background and Study Rationale Immune checkpoint inhibitors (ICI) are a breakthrough cancer treatment that boosts the immune system to fight tumors.
- Conditions
- Liver Injury, Secondary to Immune Checkpoint Inhibitors, Cancer Patients
- Trial name
- CO-CHILI (NCT06864481)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Drug Induced Liver Injury
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
Drug-induced liver injury (DILI) can lead to potentially fatal complications, such as acute liver failure and even death. In clinical practice, glucocorticoids have been considered in some cases of DILI, especially patients with…
- Trial name
- NCT06922669
- Testing
- Methylprednisolone, Magnesium isoglycyrrhizinate, Glutathione
- Where
- China
- Volunteers
- 232 people
- Sponsor
- General Hospital of Shenyang Military Region
Drug-Induced Acute Liver Injury, Tuberculosis (TB)
Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.
Worldwide, tuberculosis (TB) infection caused by Mycobacterium Tuberculosis, remains one of the top 10 deadly diseases having a significant socioeconomic burden in the world, especially in developing countries.
- Trial name
- NCT07875322
- Testing
- Antituberculosis drugs Group
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Assiut University
Drug-Induced Liver Injury
Prevalence and Prognosis of Drug-Induced Liver Injury
Drug-induced liver injury (DILI) is an important cause of acute liver damage that occurs when prescription medications, over-the-counter drugs, herbal products, or dietary supplements harm the liver.
- Trial name
- NCT07830901
- Volunteers
- 80 people
- Sponsor
- Assiut University
Colorectal Cancer, Liver Metastases
SAMe in Prevention of Oxaliplatin-associated Liver Injury
This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury
- Trial name
- NCT06258525
- Testing
- Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cedars-Sinai Medical Center
Tuberculosis Infection, Tuberculosis Infection, Latent
Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors
The objective of this observational study is to determine how frequently isoniazid (INH) causes liver injury (hepatotoxicity) in adults treated for tuberculosis (TB) or latent tuberculosis infection (LTBI) and to understand which…
- Trial name
- INH-DILI (NCT07472348)
- Testing
- Standard isoniazid-based TB/LTBI therapy
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- ASST Fatebenefratelli Sacco
Drug-Induced Liver Injury
A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases
This is a retrospective, multicenter real-world observational study. Its main goal is to find out if Polyene Phosphatidylcholine Injection works to treat drug-induced liver injury (DILI) in adults with hematologic malignancies…
- Trial name
- PPC-HM-DILI (NCT07476885)
- Testing
- polyene phosphatidylcholine
- Volunteers
- 1,000 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Drug-induced Liver Injury
A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
This is a multi-center, prospective, non-interventional cohort study . Its primary objectives are: 1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2.
- Trial name
- DILI-P (NCT02961413)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Drug Induced Liver Disease Study Group
Alcohol-Related Liver Disease, Drug-Induced Liver Injury
Misocholic Tablets for Non-Viral Elevated Liver Enzymes
Elevated liver enzymes are common laboratory abnormalities that may result from alcohol-related liver disease, drug-induced liver injury, or non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Alcohol-Related Liver Disease, Drug-Induced Liver Injury, Non-alcoholic Fatty Liver Disease
- Trial name
- NCT07833514
- Testing
- Misocholic Tab, Silymarin (Silybum marianum)
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Hanoi Medical University
Acetaminophen, Drug-Induced Liver Injury
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study
Acetaminophen (APAP) is the most commonly used NSAIDS in clinic, and it is also a common cause of drug-induced liver injury (DILI).
- Conditions
- Acetaminophen, Drug-Induced Liver Injury, Pharmacogenetics, China
- Trial name
- PAIN (NCT04964310)
- Testing
- genetic polymorphism
- Where
- China
- Volunteers
- 339 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University